close

Agreements

1 2 3 4 251
Number of results: 5006

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-12-12 Cabaletta Bio (USA - PA) vice-president nomination Autoimmune diseases Nomination
2018-12-10 BMS (USA - NY) Vedanta Biosciences (USA - MA) Opdivo® (Nivolumab) and VE800 advanced or metastatic cancers clinical research Cancer - Oncology Clinical research agreement
2018-12-06 Biogen (USA - MA) Isis Pharmaceuticals , now Ionis Pharmaceuticals (USA - CA) antisense therapies for neurological diseases neurological diseases, neuromuscular diseases development Neurological diseases - Neuromuscular diseases - Neurodegenerative diseases Exercise of an option agreement
2018-12-06 4D Molecular Therapeutics (USA - CA) Casey Eye Institute (CEI) the Oregon National Primate Research Center (ONPRC) at Oregon Health & Science University (OHSU) (USA - OR)
  • gene therapies for degenerative retinal diseases
gene therapies for degenerative retinal diseases
  • research - development
Ophtalmological diseases Research agreement
2018-12-04 Boehringer Ingelheim (Germany) Domain Therapeutics (France) orphan G Protein-Coupled Receptors (GPCRs) research - licensing CNS diseases Licensing agreement
2018-12-04 Lundbeck (Denmark) resignation Resignation
2018-12-03 Mission Therapeutics (UK) vice president nomination Cancer - Oncology - Neurodegenerative diseases - Inflammatory diseases Nomination
2018-11-29 BMS (USA - NY) the Francis Crick Institute (UK) Cancer Research UK (UK) RUBICON, a rule book and immune atlas for combination therapy lung cancer collaboration Cancer - Oncology Collaboration agreement
2018-11-26 Intrasense (France) 12 Sigma Technologies (USA - CA) ?Discover Lung Nodule, Artificial Intelligence-based Computer Aided Diagnostics (CAD) solutions lung cancer collaboration Technology - Services Collaboration agreement
2018-11-26 RegenXBio (USA - MD) Rocket Pharmaceuticals (USA - NY) NAV AAV9 vector and two additional NAV AAV vectors Danon disease licensing Rare diseases - Genetic diseases - Cardiovascular diseases - Neuromuscular diseases Licensing agreement
2018-11-20 Santhera Pharmaceuticals (Switzerland) Idorsia (Switzerland) VBP15 (vamorolone) Duchenne muscular dystrophy licensing   Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-11-15 Mission Therapeutics (UK) Abbvie (USA - IL) deubiquitylating enzymes (DUBs) inhibitors Alzheimer's disease, Parkinson's disease R&D - research - development Neurodegenerative diseases - Neurological diseases Research agreement
2018-11-14 Nektar Therapeutics (USA - CA) vice president nomination Cancer - Oncology Nomination
2018-11-12 Nestlé Health Science (Switzerland) Aimmune Therapeutics (USA - CA) AR101 for peanut allergy food allergies including peanut allergy development Allergic diseases Development agreement
2018-11-12 Integragen (France) Google Cloud (USA - CA) SIRIUS™ and MERCURY™ collaboration Technology - Services Collaboration agreement
2018-11-10 Abbvie (USA - IL) Sandoz (Switzerland)
  • intellectual property relating to Humira®
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis licensing
  • biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with  cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases Licensing agreement
2018-11-07 Alligator Bioscience (Sweden) AbClon (Republic of Korea) AC101 HER2-expressing tumors Cancer - Oncology Exercise of an option agreement
2018-11-05 Actelion (Switzerland), now Idorsia (Switzerland) ReveraGen BioPharma (USA - MD) vamorolone Duchenne muscular dystrophy licensing Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-11-05 BioNTech (Germany) University of Pennsylvania (USA - PA) mRNA vaccine candidates research - development Infectious diseases Research agreement
2018-11-02 Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) member of the board of directors nomination Allergic diseases Nomination